Visanne will drop down from $800 a year to $380 a year or $90 for concession card holders. Those living with endometriosis will have access to more affordable treatment with the drug dienogest now ...

Visanne will drop down from $800 a year to $380 a year or $90 for concession card holders. Those living with endometriosis will have access to more affordable treatment with the drug dienogest now ...

The biological basis for male contraception was established decades ago, but despite promising breakthroughs and the financial burden men increasingly bear due to better enforcement of child ...

First new treatment for endometriosis to be added to the PBS in three decades Dienogest (Visanne) is now listed on the PBS for the first time to treat endometriosis from Sunday 1 December, following ...

A woman's beliefs about family planning practices are shaped by the culture in which she is raised. Engaging women and their partners in culturally-responsive family planning and contraception ...

Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance.

The drug Visanne (also known as dienogest) is the first endometriosis treatment to be added to the Pharmaceutical Benefits Scheme (PBS) in 30 years. Endometriosis is a chronic and often ...

The drug Visanne (also known as dienogest) is the first endometriosis treatment to be added to the Pharmaceutical Benefits Scheme (PBS) in 30 years. Endometriosis is a chronic and often debilitating ...

This is the costly secondary effect of the gender health gap — which makes the listing of the oral hormonal treatment Visanne (generic name dienogest) on the Pharmaceutical Benefits Scheme a ...